INKT: רווח נקי למניה (EPS TTM) MiNK

MiNK Therapeutics, Inc. (INKT) operates in a cash-burn mode for research, which precludes profit predictability. The rolling annual earnings per share chart visualizes this process, where the -2.25 level indicates the parameter's status. Business results are independent of the economy and instead depend on testing phases. Expected T-cell data will serve as key drivers for share price growth.
פילוחי נתונים אנליטיים מרוכזים עבור MiNK Therapeutics, Inc (INKT)

This indicator reflects the net income distributed per common share over the last four quarters. The calculation is based on the company's bottom-line profit minus all expenses and taxes, divided by the total number of securities. By analyzing the rolling annual earnings per share, an investor assesses the actual efficiency of capital generation. For MiNK Therapeutics, Inc. (INKT), this metric demonstrates financial stability while developing innovative iNKT therapies. The brand's scientific reputation in immuno-oncology directly influences the long-term trajectory of this metric.